Cambium Bio Limited (ASX:CMB)

Australia flag Australia · Delayed Price · Currency is AUD
0.2700
0.00 (0.00%)
At close: Jul 15, 2025, 4:00 PM AEST
-32.50%
Market Cap5.12M
Revenuen/a
Net Incomen/a
Shares Out18.28M
EPSn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume47,705
Average Volume15,547
Open0.2700
Previous Close0.2700
Day's Range0.2700 - 0.2800
52-Week Range0.1900 - 0.6800
Beta-0.24
RSI63.32
Earnings Daten/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications. Cambium Bio Limited is based in Paddington, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol CMB
Full Company Profile

News

There is no news available yet.